Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck, India's Sun Pharma Establish JV To Develop Novel Combinations Of Branded Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

The companies will focus on innovative branded generic combination drugs, which improve compliance and convenience, to sell in emerging markets.

You may also be interested in...

Merck, Cipla Deny Deal Talks But The Charm Of The Indian Market Stokes Speculations

MUMBAI - Merck CEO designate Kenneth Frazier's visit to India accompanied by key global leaders earlier this month sparked rumors that takeover of a large Indian company could be on Merck's wish list and Cipla - the largest home-grown company by market share - may be the likely target on the Big Pharma's radar

Pfizer, Merck Execs Share Emerging Markets Strategies - Windhover's Pharmaceutical Strategic Alliances Conference (Part 2 of 2)

During the recent Pharmaceutical Strategic Alliances Conference in New York, Pfizer's Emerging Markets Business Unit President Jean-Michel Halfon and Merck's Chief Strategy Officer and Emerging Markets R&D Senior VP Merv Turner discussed priorities in tackling emerging markets. In part one, the execs outlined the steps companies should take to set up operations in emerging markets and in this second part they share their experiences in building a presence in China.

Novartis Aims Double Edged Attack With Galvus And Jalra To Take On Merck's Januvia In India

MUMBAI - The fight for a share of India's growing diabetes drugs market is set to become more fierce as Novartis is exploring an alliance with USV for promoting its type 2 anti-diabetes drug brand Jalra (vildagliptin)


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts